Strategic Licensing Ch128.1 targets TfR with preclinical efficacy in hematologic cancers, presenting a compelling licensing or co development opportunity for oncology partners seeking a novel TfR-targeted antibody.

Outsourcing Readiness With a lean team, Klyss Biotech is well suited to engage CROs and CMOs for advanced preclinical work, IND enabling studies, and GMP manufacturing, enabling rapid progression while monetizing development services.

Oncology Focus The program targets high need indications such as multiple myeloma and select non Hodgkin lymphomas, offering partnerships with specialty pharma and academic groups for combination therapies and translational research.

California Collaboration Based in Santa Monica, the company can leverage the West Coast life sciences ecosystem for partnerships, talent access, and collaborations with regional CROs, biotech incubators, and universities.

Digital Outreach A lightweight tech stack and online presence position the company to support partner outreach, licensing discussions, and investor relations, making digital channels viable sales touchpoints.